Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects peripheral nerves and roots. CIDP has no biomarkers. It may be monophasic or ...
Everyday Health on MSN
The CIDP mindset: How to manage ‘relapse anxiety’ and medical trauma
Living with chronic inflammatory demyelinating polyneuropathy (CIDP) means managing more than physical symptoms. Learn how to handle ‘relapse anxiety’ and differentiate between normal nerve sensations ...
An inability to distinguish between CIDP and POEMS syndrome can negatively affect treatment strategies and outcomes. A 2-step protocol using conduction block and maximum/minimum cross-sectional area ...
Chronic inflammatory demyelinating polyneuropathy (CIDP) may be a rare disease, but it is one of the most common forms of neuropathy and the most common form of chronic autoimmune neuropathy. Roughly ...
Vyvgart Hytrulo (efgartigimod alfa/hyaluronidase-qvfc) is a prescription medicine that is used to treat certain muscle and nerve conditions. It is a combination of two medicines, efgartigimod alfa and ...
Everyday Health on MSN
The 'energy budget': Master the spoon theory for chronic fatigue in CIDP
Even in remission, chronic inflammatory demyelinating polyneuropathy (CIDP) fatigue can be draining. Learn how to use the spoon theory, pacing strategies, and ergonomic tools to manage your "energy ...
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a symmetric demyelinating peripheral neuropathy with either a progressive or relapsing remitting course. CIDP is both debilitating and ...
Chronic Inflammatory Demyelinating Polyneuropathy Companies such as Takeda, Sanofi, Johnson & Johnson Services, Immunovant, UCB S.A., GeNeuro, Nanjing IASO ...
Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a potential first-in-class treatment Japanese Ministry of Health, Labour and Welfare decision adds to similar ...
The present patient showed characteristic features of GBS in the acute phase with rapid progression of symptoms over several days. She partially recovered within 2–4 months of initial treatment, ...
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, acquired neurological disorder with heterogeneous presentation. It is a peripheral nerve system immune-mediated condition which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results